Hemoadsorption for Severe Ischemic Stroke

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFirst Affiliated Hospital of Wannan Medical College

About this trial

This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke

Eligibility criteria

Qualifiers

15≤ NIHSS score ≤32;

3<GCS score ≤12;

CT hypodensity area >1/2 of the MCA territory; 4.hs-CRP ≥2 mg/L at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.

Disqualifiers

Hemorrhagic transformation of PH2 type prior to randomization;

Brain herniation or decompressive craniectomy performed before randomization;

Hemodynamic instability refractory to medical correction (systolic blood pressure <70 mmHg or diastolic blood pressure <50 mmHg) or decompensated heart failure (NYHA Class III or IV);

Severe hepatic impairment (defined as ALT >2 times the upper limit of normal or AST >2 times the upper limit of normal) and renal impairment (defined as serum creatinine >1.5 times the upper limit of normal or estimated glomerular filtration rate [eGFR] <50 mL/min);

Trial design

Treatments tested in this trial

  • Hemoadsorption

Treatment groups

116 Participants
are divided into 2 treatment groups

Sponsors and collaborators

First Affiliated Hospital of Wannan Medical College

Lead sponsor

Anqing Municipal Hospital

Collaborator

Beijing Tiantan Hospital

Collaborator

Gansu Provincial Central Hospital

Collaborator

Baotou Central Hospital

Collaborator

The NO.1 People's Hospital of Shizuishan

Collaborator

Fuyang people's hospital

Collaborator

Second People's Hospital of Hefei City

Collaborator

The First Affiliated Hospital of Zhengzhou University

Collaborator

THE SECOND PEOPLE'S HOSPITAL, WUHU

Collaborator